Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: A phase I/II study in Japanese patients

Japanese Journal of Clinical Oncology

Volumn 38, Issue 5, 2008, Pages 339-346

  Nakagawa, Kazuhiko ^a   Yamazaki, Koichi ^b   Kunitoh, Hideo ^c   Hida, Toyoaki ^d   Gemba, Kenichi ^e   Shinkai, Tetsu ^f   Ichinose, Yukito ^g   Adachi, Susumu ^h   Nambu, Yoshihiro ^h   Saijo, Nagahiro ⁱ   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OKAYAMA ROSAI HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h ELI LILLY AND COMPANY   (United States)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cisplatin; Mesothelioma; Pemetrexed; Phase I II

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; MULTIVITAMIN; PEMETREXED;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; ERYTHROCYTE COUNT; ERYTHROPENIA; FEMALE; FEVER; HEADACHE; HICCUP; HUMAN; JAPANESE; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAGNESIUM BLOOD LEVEL; MALAISE; MALE; MALIGNANT PLEURA MESOTHELIOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEINURIA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UREA BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 44449165444     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn024     Document Type: Article

References (16)

1. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56: 250-65.
2. Carter SK. Study design principles in the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ. editor. The Design of Clinical Trials in Cancer Therapy. Brussels, Belgium: Futara Pub Co 1973;242-89.
3. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
4. Eguchi K, Kurihara M, Shimozuma K, Hotta T, Murakami M, Suzuki N, et al. Quality of life questionnaire for cancer patients treated with anticancer drugs. Nippon Ganchiryo Gakkaishi 1993;28:1140-4 (in Japanese).
5. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
6. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium a novel antifolate clinically active against multiple solid tumors. Oncologist 2001:6:363-73.
7. 12 in Japanese patients with solid tumors. Br J Cancer 2006:95:677-782.
8. Pass HI, Hahn SM, Vogelzang NJ, Carbone M. Benign and malignant mesothelioma-Chapter 36. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors Cancer Principles and Practice of Oncology. 7th edn. Philadelphia: Lippincott Williams & Wilkins 2004:1687-715.
9. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
10. Saijo N and Study Group. Guideline for phase I/II study on anticancer drugs (Draft version). Med Front (Saishin Igaku) 2001;56:1515-41 (in Japanese).
11. Shih C, Habeck LL, Mendelsohn LG, Chen VJ. Schultz RM. Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-52.
12. Taylor EC, Patel HH. Synthesis of pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-(2-amino-4(3H)- oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid (LY231514). Tetrahedron 1992;48:8089-100.
13. The International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-8.
14. The Japanese Respiratory Society. In: Clinical Pulmonary Functions Committee, editor. Guideline of Pulmonary Function Test. Tokyo: Medical Review 2004 (in Japanese).
15. Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marek EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005:23:6881-9.
16. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel F, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Opin Oncol 2003;21:2636-44.